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1. Introduction
Although until recently it is presumed that the greater portion of the genome has no biological
role, the current advances in genome research and RNA biology have provided evidence
indicating that a large section of the human and most eukaryotic genome is transcribed as non-
protein-coding RNAs or non-coding RNAs (ncRNAs)[1,2]. Only about 2% of the eukaryotic
genome sequence codes for protein encoding genes and the remaining so called “junk” DNA
are thought to have no functional significance [3, 4]. Based on large scale studies of human and
other eukaryotic genomes it is estimated that about 98 % of the transcriptional output of their
genomes is RNA that does not encode protein implying that the genomes are gorged with
either inept RNA transcripts or with ncRNA transcripts that exhibit unanticipated functions
in eukaryotic biology. However, recent development of new technologies in molecular biology
and human genetics such as genome tiling [4,5], microarrays, and next generation RNA-
sequencing (RNA-Seq) [6,7] have enabled the discovery of different types of ncRNAs that do
not code for protein product [8-10]. Even though ncRNAs do not encode proteins, they play
pivotal roles in the complex networks that are necessary to regulate cellular functions via
transcriptional and translational regulation of protein coding genes that are crucial to normal
development and physiology, and to disease [11]. Moreover, many of the ncRNAs are highly
conserved and susceptible to epigenetic and genetic defects that affect normal development
and disease process significantly [12-15].
There are copious non-coding transcripts that participate principally in regulating cellular
protein synthesis, which are grouped into different classes based on their size, function and
association with transcription start site [1, 12, 16-18]. According to their size, ncRNAs are
categorized into: small ncRNAs, 20 to 200 nucleotides long, which includes microRNAs
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(miRNAs), PIWI-interacting RNAs (piRNAs) and small nucleolar RNAs (snoRNAs); long
ncRNAs (lncRNAs) that are longer than 200 nucleotides; and macro ncRNAs, longer than 200
nucleotides that can reach 100 kilobases (kb) longer without being processed into small
ncRNAs [1,7,12,18]. Based on where they are derived from within the genome, lncRNAs can
be distinguished from each other. There are intronic lncRNAs (transcribed between exons of
genes), intergenic lncRNAs (transcribed from the space between two genes) and lncRNAs that
are derived from the regions that overlap both exon and intron of a coding gene. Furthermore,
each of these ncRNAs may also be in the sense or in the antisense direction. According to
functional significance, ncRNAs can be divided into: (1) housekeeping ncRNAs and (2)
regulatory ncRNAs. Housekeeping ncRNAs include constitutively expressed ncRNAs that are
crucial for the normal function and cellular viability, which include transfer RNAs, ribosomal
RNAs, small nuclear RNAs, and snoRNAs [18]. On the contrary, regulatory ncRNAs or
riboregulators include ncRNAs such as miRNAs and lncRNAs that are expressed in response
to external signals, during different cellular states such as cellular differentiation or at certain
stages of development, influencing the expression of other genes at transcription and transla‐
tional levels [1, 7, 12, 18]. Regarding ncRNAs that are associated with transcription start sites
of genes, there are different classes of ncRNAs such as promoter-associated small RNAs
(PASRs) [16], transcription start site-associated RNAs (TSSa-RNAs) [19], promoter upstream
transcripts (PROMPTs) [20] and transcription initiation RNAs (tiRNAs) [21]. Even though their
functional roles are poorly delineated, perhaps they have a regulatory role in transcription.
Among the ncRNAs, the most widely studied and comparatively well delineated regarding
their functional relevance to normal development and physiology, and to pathogenesis of
disease are, small microRNAs [1, 12, 22-25]. miRNA deficiencies or surpluses have been
correlated with diverse clinically important diseases including various types of cancers,
neurological diseases, metabolic diseases, cardiovascular diseases, and many others [22,
25-32]. Here, we provide an overview of the current knowledge of miRNAs that participate in
the regulation of vascular smooth muscle cells (VSMC) phenotypic modulation and present
the potential opportunities for miRNA-based therapeutic and diagnostic approaches for
vascular proliferative diseases due to atherosclerosis and restenosis. Finally, we briefly
describe our preliminary unpublished data on miRNA expression profile of VSMC in response
to butyrate, a histone deacetylase (HDAC) inhibitor.
2. Atherosclerosis and restenosis
Vascular cell activation and remodeling are the principle events in vascular pathologies such
as atherosclerosis, transplant vasculopathy, post angioplasty restenosis, in-stent restenosis and
bypass graft failure [33, 34]. It is realized that injury to vessel wall by various atherogenic
insults sets-off inflammatory response causing endothelial cell dysfunction. Following
endothelial cell dysfunction, VSMC in the media that are quiescent and contractile in nature,
migrate to intima in response to local inflammation and become proliferative cells. VSMC are
highly specialized cells whose principal function is to regulate the attributes of blood vessels
in the body by appropriately responding to changes in the volume of blood vessels and the
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local blood pressure to facilitate distribution of oxygenated blood to different parts of the body.
In adult vessels, VSMC proliferate at very low rate; display reduced synthetic activity; and
express a unique compilation of proteins that is characteristic of contractile phenotype such as
contractile proteins, ion channels, and signaling molecules. Yet, they still maintain remarkable
plasticity and retain the ability to undergo extreme and reversible changes in phenotype in
response to their local environmental signals, especially during vascular development, and in
response to vascular injury as a key mechanism in wound healing. It is recognized vascular
injury provoked by various atherogenic insults such as mechanical, chemical and immuno‐
logical injuries triggered by different disease risk factors promote VSMC activation, migration
and proliferation, which are precursors to the development of atherosclerosis and neointimal
hyperplasia [34, 35]. VSMC also undergo phenotypic modification from contractile to prolif‐
erative or synthetic phenotype in conjunction with vessel remodeling by altering the cell
number and composition of vessel wall as the primary pathophysiological mechanism in
different clinical pathologies such as postangioplasty restenosis, in-stent restenosis, and vein
bypass graft failure and transplant vasculopathy [34-37]. However, the molecular mechanisms
involved in VSMC phenotypic control are still vague.
During the last few years there is an upsurge in ncRNA research specifically pertaining to a
novel class of small miRNAs because of their role in various biological functions. In a variety
of eukaryotic organisms miRNAs have been demonstrated to play key roles in various cellular
processes including proliferation, differentiation, and apoptosis [38-40], which are central to
normal development and physiology, and pathogenesis of diseases. As such, dysregulation of
miRNAs has been linked to different diseases, including different cancers, neurological,
cardiovascular and other diseases [22, 25-32]. Because of their effects on cellular processes as
gene expression regulators, impairment of miRNAs as evidenced in many cancers, suggest
involvement of miRNAs in the phenotypic modulation of VSMC both in normal and disease
states. Here we briefly describe miRNAs, their biogenesis and mechanism of action and then
summarize the recent progress in the functional significance of miRNAs in VSMC phenotypic
modulation and response to injury.
3. miRNAs
miRNAs are endogenous, well conserved, small ncRNAs, usually 20 to 26 nucleotides, that
mediate posttranscriptional gene silencing by complimentary binding to the 3’-untranslated
region (3’-UTR) of their target mRNA, leading to direct target mRNA degradation or transla‐
tional repression, a key phenomenon for controlling gene expression in a tissue- and devel‐
opment-specific manner [1, 38-40]. They were first detected in Caenorhabditis elegans as
regulators of development in 1993 [41] and since then they have been found in many species
of plants and animals. There are several differences between plants and eukaryotic mRNAs.
In plants, transcriptional repressions require a perfect or near-perfect target match, whereas
mismatched target can cause gene silencing at the translational level in eukaryotes. In eukar‐
yotes, miRNA complementarity typically includes the 5’ bases 2-7 of the miRNAs, which is
referred as miRNA “seed” region, Furthermore, one miRNA can target many different sites
MicroRNAome of Vascular Smooth Muscle Cells: Potential for MicroRNA-Based Vascular Therapies
http://dx.doi.org/10.5772/54636
149
on the same mRNA or many different mRNAs, and a single mRNA can be under stringent but
redundant control of several miRNAs. Another difference is the location of target sites on
mRNAs. In eukaryotes miRNA target sites are in the 3’-UTRs of the mRNAs. In plants, target
sites are normally in the coding region but they can be present in the 3’-UTRs.
miRNAs are predicted to target about 60% of protein coding transcripts [12, 42, 43]. At present
the number of miRNA sequences deposited in miRBase (Release 16) include over 15,000
miRNA loci, expressing over 17,000 distinct mature miRNA sequences from 142 species [44].
Moreover, recent appreciation in miRNA research in eukaryotes implicates that these key gene
expression regulators control various biological processes as diverse as cell proliferation, cell
differentiation, apoptosis, and stem cell division particularly in mammalian development
[38-40, 45]. In spite of tremendous advances in miRNA research, the role of miRNAs in
physiological and pathophysiological processes is just emerging. Recent miRNA expression
studies demonstrate miRNAs in cardiovascular development [46], brain development [47],
viral infection [48], metabolism [29], different types cancer, neurologic and cardiovascular
diseases [22, 25-32] suggesting link between miRNAs and wide range of tissue development
and diseases. In effect, miRNAs are considered as trans-acting gene regulatory molecules,
similar to and as important as transcription factors in the control of gene expression [49].
Although miRNAs are considered to act as intracellular RNAs to control gene expression at
posttranscriptional level, recent studies have detected miRNAs in circulating blood and in cell
culture medium indicating they may be useful as biomarkers of disease [50, 51].
4. Biogenesis of miRNAs
The transcription of miRNAs depends on their location within the genome. Most of the miRNA
genes are located throughout the genome in introns, exons and intergenic regions with many
miRNAs produced from clusters of coexpressed genes. Some miRNA transcription depends
on same RNA polymerase II promoters that drive the transcription of mRNAs. miRNA genes
located in intronic regions that includes half of known miRNAs genes often depend on the
expression of host gene [52, 53]. Some miRNA genes with independent promoters are tran‐
scribed from their own RNA polymerase II promoters. Additionally a small number of
miRNAs genes are transcribed by RNA polymerase III. Those miRNAs organized in clusters
for example, miRNA-17-92-family, share the same transcriptional regulation and are grouped
together in one cluster on a single unprocessed transcript and expressed together [54].
5. The pathway of miRNA biogenesis and gene silencing
The process of miRNA biogenesis starts in the nucleus as depicted in the following Figure [12,
31, 32]. miRNAs are transcribed as hundreds or thousands of base long large primary miRNA
species (pri-miRNA) by RNA polymerase II or RNA polymerase III. These pri-miRNA
transcripts fold into a stem loop or hairpin structures with capped 5’ end and polyadenylated
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(poly A) tail on 3’ end [55]. Following transcription by RNA polymerase II/III, pri-miRNA
transcripts are trimmed to about 60 to 100 nucleotide hairpin structures with ~2 nucleotide 3’
overhang to form precursor miRNAs (pre-miRNAs) by the action of nuclear microprocessor
complex. Microprocessor complexes are formed of Drosha (RNASEN), a nuclear ribonuclease
RNase III enzyme and its partner DGCR8 (DiGeorge critical region 8) also called as Pasha
(Partner of Drosha). The pre-miRNA transcripts are then shuttled to cytoplasm for further
processing via Exportin5 and Ran-GTP6. Pre-miRNAs are processed further in the cytoplasm
by the action of Dicer, another RNase III enzyme, with the assistance of double-stranded RNA
binding proteins (dsRBPs) including TRBP (tar RNA binding protein), resulting in the cleavage
of hairpin loop of pre-miRNAs leading to formation of ~22 nucleotide mature miRNA
duplexes. Mature duplex is composed of a matured miRNA strand referred as guide strand
and a complimentary strand referred as the passenger strand. The gene silencing capability
depends on Dicer-mediated loading of one of the miRNA strands, usually guide strand, in the
RNA-induced silencing complex (RISC) together with Argonaute (Ago) protein. The RISC
guides the miRNA to bind to its complementary sequence within the 3’-UTR of its target
mRNA. The degree of complementarity between the seed sequence of the miRNA and the 3’-
UTR of its target mRNA determines whether to mediate mRNA degradation or to disrupt
translation.
6. MicroRNAome of VSMC
miRNAs are relatively new regulatory molecules that are identified about a decade ago and
demonstrated to have regulatory role in every organism and in every biological functions
influencing normal biology and disease process. Once again, oncology research is in the
leading position in understanding miRNA involvement in human diseases. Although most of
the miRNA knowledge is coming from cancer research, during the past few years their role in
other systems and diseases are emerging and rapidly being evaluated with new technologies
such as deep sequencing. It is not surprising that interest in miRNA is also on the raise in
cardiovascular research field. Literature on the roles and functions of miRNAs in normal
cardiovascular development and in vascular pathologies is escalating [32, 46, 56-60]. Further‐
more, importance of miRNAs in the regulation of VSMC development and phenotypic
modification, and response to injury is swiftly being explored because VSMC proliferation and
migration are important events in vascular proliferative diseases. Here we will summarize
recent updates on the significance of miRNAs in VSMCs and their role in phenotypic modu‐
lation of VSMC, thus to vascular proliferative diseases [32, 57-60]. Most of the knowledge of
VSMC miRNAs is coming from culture cells, animal models and blood samples of cardiovas‐
cular disease patients.
7. Evaluation of essential role of miRNAs in VSMC
Because activity of Dicer is essential for the miRNA processing, loss of Dicer activity should
result in global loss of miRNAs. Importance of miRNAs for VSMC development and biolo‐
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gy can be validated by knocking out the miRNA processing enzyme Dicer in VSMC. To
demonstrate the importance of miRNAs in VSMC development and function, a smooth
muscle restricted -Dicer knockout model, SM-Dicer KO mice, is investigated recently [59,61].
Outcomes of the study indicate deletion of Dicer causes embryonic lethality due to de‐
creased VSMC proliferation and differentiation resulting in thinner vessel walls, impaired
contractility and hemorrhage as well as reduced expression of VSMC-specific genes and
proteins [59, 61]. Overall, these observations suggest that Dicer-generated miRNAs are cru‐
cial for normal VSMC development, differentiation and contractile function.
Figure 1. Biogenesis of miRNA and gene silencing pathway. The miRNA synthesis starts in the nucleus where pri-
miRNA transcript is cleaved by Drosha/ DGCR8 to form ~60-100 nucleotides long hairpin loop pre-miRNA. Pre-miRNA
is then transported to cytoplasm through the mediation of Exportin5 and Ran-GTP6 where it is further processed by
RNase activity of Dicer to ~22 nucleotides mature miRNA duplex. The miRNA duplex then loads onto Ago in the RISC
complex and undergoes strand separation. The guide strand of the miRNA mediates gene silencing by degrading the
target mRNA or interfering with translational process. The passenger strand gets degraded.
8. miRNA regulation of VSMC phenotype
VSMC exhibit remarkable plasticity by adapting to local conditions via phenotypic modula‐
tion. Phenotypic modulation of VSMC is a highly complex process regulated by transcription
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factors and other gene products and multiple pathways that are still vaguely understood.
Recently several reports have demonstrated the involvement of miRNA-mediated gene
silencing in the regulation of VSMC proliferation, migration and differentiation in normal
vascular development and in vascular pathologies. A list of a few selected miRNAs that
regulate VSMC proliferation and differentiation in cell cultures and animal models with
angioplasty is shown in Table 1 along with factors that regulate miRNA expression, their
validated target proteins and function of the target proteins. While some of these miRNAs
promote VSMC proliferation, others stimulate differentiation.
microRNA Inducer/Regulator Target Proteins
Cellular Functions of Target
Proteins References
miRNA 21 Vascular injury PTEN,Bcl2
Increase proliferation,
apoptosis 62
miRNA 221/222 Injury,PDGF
p27kip1,
p57kip2 Increase proliferation 63
miRNA -146a KLF5 KLF4 Increase proliferation 64
miRNA 26a Serum deprivation Smad 1, Smad 4 Decrease proliferation 68
miRNA 143 p53, SRF/Myocardin PDGFR, Elk1
Decrease proliferation,
stimulate differentiation 58
miRNA 145 SRF/ Myocardin CamKIIδ, KLF4,KLF5
Decrease proliferation
stimulate differentiation 58,65
Table 1. miRNAs regulating vascular smooth muscle cell phenotype
9. miRNAs in the mediation of VSMC proliferation
Some miRNAs, such as miR-21, miRNA-221, miRNA-222 and 146a are demonstrated to
promote VSMC proliferation in balloon-injured rat carotid arteries and cultured rat VSMC by
silencing their target proteins (Table 1). Among these, miRNA-21 is the first miRNA that is
recognized to regulate VSMC growth and survival by silencing phosphatase and tensin
homolog (PTEN), a tumor suppressor protein and increasing B-cell lymphoma 2 (Bcl-2), which
increased VSMC proliferation and survival [32,59-62]. Interestingly, this same miRNA is
shown to regulate features of both proliferative and contractile phenotype by separate
mechanisms. Through the regulation of processing of the miRNA-21 primary transcript to the
mature miRNA -21 transcript, transforming growth factor-β (TGF-β) and bone morphogenetic
proteins (BMPs) increased the miRNA-21. This increased miRNA-21 is shown to promote
VSMC differentiation by upregulating VSMC restricted contractile proteins by silencing
programmed cell death 4, a tumor suppressor protein [63].
Other miRNAs that stimulated proliferative phenotype include miRNA-221 and -222. Their
proliferative effect on VSMC is mediated through silencing of their target proteins, p27kip1
and p57kip2, respectively, both of which are negative regulators of cell cycle progression [32,
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64]. miRNA-146a is shown to directly target Krupple-like factor-4 (KLF-4) and promote VSMC
proliferation in cultured rat VSMC and vascular neointimal hyperplasia [32, 60, 65]. KLF-4 and
miRNA-146a appear to exhibit a feedback relationship regulating each other’s expression.
While miRNA-146a inhibits KLF-4 expression by targeting the 3’-UTR region of KLF-4, KLF-4
inhibits miRNA-146a at the transcriptional level. KLF-5, another member of KLF family
promoted the transcription of miRNA-146a. It appears these molecules form a regulatory
control to appropriately modulate VSMC proliferation [32, 60].
10. miRNAs in the suppression of VSMC proliferation
Certain miRNAs including miRNA-143, miRNA-145 and miRNA-26a alter VSMC phenotype
by causing suppression of VSMC proliferation (Table 1). Among these miRNAs, miRNA-143
and -145 are considered master regulators of contractile phenotype by promoting contractile
protein expression [32, 58, 60]. Moreover, miRNA-145 not only stimulates differentiation of
adult VSMC, but also promotes differentiation of multipotent neural crest stem cells into
VSMC [57]. In normal vessel walls the miRNA-143/145 cluster is lavishly expressed. However,
both miRNAs are dramatically reduced not only in injured carotid arteries following angio‐
plasty [32, 58, 60, 66] but also downregulated in different cancer cell lines [67]. Further studies
proved that miRNA-145 is a critical modulator of VSMC differentiation via its target gene
KLF-5. Consistent with this, while the use of miRNA-145 oligonucleotide mimics upregulated
the expression of VSMC differentiation marker genes such as SM α-actin, calponin, and SM-
MHC, both at gene and protein levels, overexpression of KLF-5 reduced the gene expression
of SM α-actin implicating a relationship between miRNA-145 and KLF-5 gene in VSMC
differentiation.
Analysis of growth arrested human aortic VSMC by miRNA array screening identified
upregulation of miRNA-26a in differentiated VSMC, which is associated with reduction in
SMAD activity [59, 60, 68]. This miRNA is dramatically downregulated in two murine models
of aneurysm.
Embryonic stem cells are known to differentiate to VSMC and one of the factors that induces
VSMC differentiation is all trans retinoic acid, which in addition to regulating a wide variety
of protein coding genes it also regulates expression of miRNAs that affect smooth muscle cell
differentiation. It is found that expression of miRNA-10a contributes to retinoic acid-induced
VSMC differentiation by negatively regulating its target histone deacetylase 4 [69]. Involve‐
ment of miRNAs in stem cell and vessel wall progenitor cell differentiation has significant
implications in the pathogenesis of atherosclerosis, the response to vascular injury and
vascular remodeling.
11. Circulating miRNAs
Recently presence of miRNAs is demonstrated in circulating blood, which may be useful as
biomarkers for diseases [51]. Analysis of serum or plasma for circulating levels of miRNAs in
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normal individuals and in patients with coronary artery disease revealed circulating levels of
angiogenesis-related miRNA-126 and miRNA-92a, the inflammation-associated miRNA-155;
and VSMC-enriched miRNA-145 and miRNA-17 are significantly reduced in patients with
coronary artery disease compared to normal individuals [51]. Whereas cardiac muscle-
enriched miRNAs, miRNA-133a and -208a are elevated in patients with disease. These
observations suggest that circulating miRNAs can be used as biomarkers for diagnosis of
cardiovascular diseases.
12. miRNAs in atherosclerosis and neointimal hyperplasia
Although  roles  of  various  miRNAs and  their  participation  in  biological  processes  have
been  recognized  in  various  cultured  cells  or  animal  models,  and  expression  profiles  of
circulating miRNAs in patients of cardiovascular diseases [50, 51], involvement of miRNAs
in human atherosclerotic plaques has received little attention. However, one of the recent
studies investigated miRNA/mRNA expression profiles of human atherosclerotic plaques
from peripheral arteries in comparison to nonatherosclerotic left internal thoracic arteries
to determine the relationship between miRNA/mRNA expression profiles  and biological
processes  in  atherosclerosis  [70].  Results  of  this  study  revealed  significant  amounts  of
miRNA-21,-34a,  -146a,  -146b-5p,  and  -210  expressions  in  atherosclerotic  lesions.  Consis‐
tent with this there was downregulation of several predicted targets of these miRNAs in
atherosclerotic  plaques.  According  to  the  combination  of  miRNA/mRNA  profiles  and
bioinformatic  analysis,  nine  KEGG  pathways  including  immunodeficiency,  metabolism,
p53  and  cell  proliferation  signaling  pathways  enriched  with  predicted  targets  were
significantly upregulated. On the contrary, VSMC contraction and purine metabolism were
downregulated.
13. miRNAs in restenosis
Role of miRNAs in restenosis is mainly studied using the common rat carotid artery balloon
injury animal model. miRNA profiles in the carotid artery is determined by using miRNA
arrays [62]. One of the miRNA that was aberrantly overexpressed in injury-induced neointimal
lesions is miRNA-21. miRNA-21 promotes VSMC proliferation and inhibits apoptosis of
VSMC by directly targeting PTEN and programmed cell death 4, respectively [32]. Similarly
miRNA-221 and -222, which are encoded by a gene cluster on X chromosome, share the same
seed sequence, identical targets and similar functions were upregulated in balloon-injured
carotid arteries. Consistent with their upregulation, their target genes, p27kip1 and p57kip2
were downregulated [32, 64]. Additionally, miRNA-143 and miRNA-145 that promote VSMC
differentiation and expressed highly in vascular tissue, were significantly reduced in apoli‐
poprotein E knockout mice where vascular injury was induced by hypercholesterolemic diet
[71]. Cooperatively, both miRNA-143 and miRNA-145 target a network of transcription factors
such as Elk1, KLF-4 and myocardin to stimulate differentiation and inhibit proliferation of
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VSMC. Taken together, these studies indicate significant role of miRNA-143/miRNA-145 in
VSMC differentiation and vascular disease.
14. miRNAs in histone deacetylase (HDAC) inhibitor arrested VSMC
proliferation
Butyrate, a dietary-derived epigenetic histone modifier and a histone deacetylase (HDAC)
inhibitor, is a strong inhibitor of VSMC proliferation [72-75]. Butyrate elicits many cytoprotec‐
tive,  chemopreventive  and chemotherapeutic  activities  mainly  through inhibition  of  cell
proliferation, induction of cell death or stimulation of cell differentiation by selectively modulat‐
ing gene expression via epigenetic changes [72-75]. Incidentally, the cellular effects that are
stimulated by butyrate are also regulated by miRNAs and expression of some of these miR‐
NAs is regulated by epigenetic mechanisms including DNA methylation and histone modifica‐
tion [76, 77]. Because butyrate is an established epigenetic histone modifier it is possible that
butyrate may alter expression of some of the miRNAs in butyrate arrested VSMC proliferation.
To explore this possibility, we recently examined expression profile of 650 miRNAs in butyrate
inhibited rat VSMC proliferation by qRT-PCR array platform. Our preliminary unpublished data
indicates differential expression of about 60 miRNAs. Among these, members of the miR‐
NA-17-92 cluster are some of the miRNAs that are downregulated by butyrate in VSMC
suggesting that antiproliferation action of butyrate is linked to downregulation of miRNAs of
miRNA-17-92 cluster (Table 2). Studies have shown that the miRNAs of this cluster are not only
involved in normal development of heart, lung and immune system but they also exhibit essential
role in tumor formation by promoting cell proliferation and suppressing apoptosis [78].
miRNA-17-92 cluster
mature miRNAs Fold change *
rno-miR-17-1-3p -2.77
rno-miR-17-2-3p -2.65
rno-miR-17-5p -2.15
rno-miR-18a* -1.80
rno-miR-19a -2.26
rno-miR-19a* -2.31
rno-miR-19b -2.32
rno-miR-19b-1* -2.84
rno-miR-20a* -2.40
rno-miR-92a -2.45
rno-miR-92a-1* -8.62
*Values represent fold changes relative to untreated rat VSMC.
Table 2. Changes in miRNA-17-92 cluster mature miRNAs levels in butyrate treated rat VSMC
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The miRNA-17-92 cluster is a polycistronic miRNA gene, which is titled as oncomir-1 in
humans because of their oncogenic properties and overexpression in different cancers [79].
The miRNA-17-92 primary transcript encodes six mature miRNAs: miRNA-17,-18a, 19a, 20a,
19b-1, and 92a-1 that are tightly grouped within an 800 base-pair region of human chromosome
13 [80]. For some of these members corresponding target genes have been identified, which
include cell cycle inhibitor CDKN1A (p21Cip1) and pro- apoptotic PTEN and BCL2L11 (Bim).
Furthermore, transcription of miRNA-17-92 has been shown to be activated by c-myc tran‐
scription factor [78]. In our earlier studies butyrate has been shown to downregulate c-myc [81]
and upregulate CDKN1A (p21Cip1) [72-75] in proliferation inhibited VSMC. Based on these
observations, it appears by downregulating c-myc expression potentially via epigenetic
modification, butyrate inhibits expression of miRNA-17-92 cluster with a corresponding
increase in miRNA-17-92 target genes such as CDKN1A (p21Cip1). Taken together, our
preliminary miRNA expression data emphasizes role of miRNAs in antiproliferative and
chemoprotective effects of butyrate in VSMC. Further studies are under investigation to
confirm the role of miRNA-17-92 cluster in the regulation of VSMC proliferation by investi‐
gating the effects of miRNA mimics of miRNA-17-92 cluster in reversing the effect of butyrate
on VSMC proliferation and on decreasing the levels of their target proteins. Utilization of this
information is beneficial in targeting miRNAs aimed to decrease the level of pathogenic/
aberrantly expressed miRNAs or to increase miRNAs with valuable functions in the interven‐
tion of occlusive vascular proliferative diseases.
15. miRNAs as new therapeutic targets for vascular proliferative diseases
Despite the substantial progress in understanding the etiology and clinical management of
vascular proliferative diseases, they are still life threatening diseases responsible for the global
burden of cardiovascular diseases. Clinically, medications and surgical procedures are the only
methods of treatment for patients with atherosclerotic disease. Atherosclerotic patients are
generally treated by angioplasty with stent replacement but it commonly leads to restenosis
in significant number of angioplasty patients. Phenotypic modification of VSMC from
contractile differentiated state to proliferative dedifferentiation state is the primary pathophy‐
siological mechanism in the development of atherosclerosis and in different clinical patholo‐
gies such as postangioplasty restenosis, in-stent restenosis, vein bypass graft failure and
transplant vasculopathy [33,34]. Therefore, understanding the molecular mechanisms of
VSMC proliferation may offer novel insights into disease pathogenesis leading to targeted
therapies. Vascular phenotypic modulation is a multifactorial process involving multiple
pathways and multiple genes. Based on the current understanding of the roles of miRNAs in
the normal development and in disease pathogenesis, it appears miRNA-based therapy has a
potential in vascular proliferative diseases, particularly because one endogenous miRNA can
target its multiple target genes. Moreover, demonstration of changes in expression of certain
miRNAs that is specifically associated with particular VSMC phenotype in different models
of studies, as depicted in this article, clearly suggests that expression analysis of miRNA will
provide insights into vascular proliferative disease mechanisms and possibly identifies novel
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targets for future vascular therapy. This information is important in targeting miRNAs aimed
to decrease the level of abnormally expressed miRNAs and/or to increase miRNAs with
valuable functions in the intervention of occlusive vascular proliferative diseases.
The  recent  demonstration  that  changes  in  expression  of  certain  miRNAs  in  neointimal
lesions, particularly upregulation of miRNA-21 and miRNA-221/-222 and downregulation
of miRNA-145 support proliferative phenotype of VSMC suggests targeting miRNAs may
represent a new form of therapy for vascular proliferative diseases [62, 64]. Furthermore,
silencing  of  miRNA-21  and  miRNA-221/222  by  the  local  delivery  of  chemically  engi‐
neered oligonucleotide-based miRNA inhibitors referred as “antigomirs” are efficient and
specific  silencers  targeted  for  miRNA-21  and  miRNA-221/222  was  shown  to  reduce
neointima formation [62, 64]. Similarly, use of an antagomir against miRNA -122, specifical‐
ly silenced miRNA-122 expression in the liver, lung, intestine, heart, skin and bone marrow
for more than a week after one intravenous injection [82]. In another method, silencing of
mir-145 or miRNA- 143 was achieved by adenovirus-mediated delivery of these miRNAs
to vascular lesion, which appears to restore miRNA profile of vascular lesion that resem‐
bles  normal  tissue [66,  71].  Although these  studies  suggest  that  targeting miRNAs may
represent a new therapy for vascular proliferative diseases, the miRNA-based technology
is still long way from being translated to clinical therapy.
16. Conclusion
Exploring the microRNAome that controls VSMC phenotype and analysis of their targets have
greater possibilities for unraveling unforeseen regulatory pathways and disease mechanisms,
development of novel therapeutic approaches. miRNAs in cardiovascular research are a newly
emerging powerful biomolecules, which demonstrate several unique opportunities for
microRNAs-based therapeutics. Although some of the studies appear to indicate targeting
certain miRNAs presents a potential therapy for atherosclerosis, knowledge of full scope of
miRNAs in vascular pathogenesis is limited. With 1,000 or more microRNAs encoded by the
human genome, only a few of which have been analyzed appear to be linked to vascular
proliferative diseases. Considering the complexity of the multifactorial vascular proliferative
diseases including atherosclerosis and restenosis, there may be several miRNAs and even
several clusters of miRNAs, similar to miRNA-17-92 cluster, which impact the development
of vascular pathogenesis. Therefore, several issues have to be addressed prior to use of miRNA-
based technology can be translated to clinical therapy such as: profile of miRNAs responsible
for vascular proliferative diseases needs to be determined; detailed effects of these miRNAs
in the prevention and treatment of vascular proliferative diseases requires investigation;
procedures for in vivo miRNA silencing needs to be improved to minimize off-target effects;
technology for miRNA upregulation in arterial vessel wall requires development; and
potential toxicity of miRNA-based therapy should be determined. Developing miRNAs into
therapeutics reveals other significant challenges, such as methods of delivery and duration of
action. Methods for local delivery to the arteries via catheters or coated stents may avert these
challenges and should minimize off-target effects on other tissues. Besides their therapeutic
Current Trends in Atherogenesis158
potential, identification of circulating miRNAs released from injured tissues or highly
expressed in patients with cardiovascular diseases suggest miRNAs can also be useful as
potential biomarkers for clinical diagnosis of cardiovascular disease patients.
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